An on-going phase II “basket” study of vemurafenib in non-melanoma solid tumors harboring BRAF mutations demonstrated stable disease at 8 wk in 4/7 CCA patients, partial response in 2/7 at 24 wk and the remaining 1/7 with disease progression (clinical trial # NCT01524978). Here, BRAF is linked to cholangiocarcinoma.